{"organizations": [], "uuid": "8d4f66ee798a1b2c9e9afccede3963782cc8b8e8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-icer-says-spark-therapeutics-gene/brief-icer-says-spark-therapeutics-gene-therapy-price-too-high-idUSL1N1P717V", "country": "US", "domain_rank": 408, "title": "BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-12T18:57:00.000+02:00", "replies_count": 0, "uuid": "8d4f66ee798a1b2c9e9afccede3963782cc8b8e8"}, "author": "", "url": "https://www.reuters.com/article/brief-icer-says-spark-therapeutics-gene/brief-icer-says-spark-therapeutics-gene-therapy-price-too-high-idUSL1N1P717V", "ord_in_thread": 0, "title": "BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High", "locations": [], "entities": {"persons": [{"name": "bill berkrot", "sentiment": "none"}], "locations": [], "organizations": [{"name": "icer", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "too high reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 12, 2018 / 4:58 PM / Updated 6 minutes ago BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High Reuters Staff 1 Min Read \nJan 12 (Reuters) - Spark Therapeutics Inc: \n* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH \n* ICER SAYS $850,000 PRICE FOR LUXTURNA BLINDNESS TREATMENT SHOULD BE 75-82 PERCENT LOWER BASED ON VALUE ASSESSMENT \n* ICER RECOMMENDS LUXTURNA PRICE BETWEEN $153,000 AND $217,000 FOR ONE-TIME GENE THERAPY Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)", "external_links": [], "published": "2018-01-12T18:57:00.000+02:00", "crawled": "2018-01-12T19:15:09.022+02:00", "highlightTitle": ""}